Overview

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Treatments:
Bevacizumab
Cetuximab
Irinotecan
Raltitrexed